Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Osaki

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Nihon Sanka Fujinka Gakkai Zasshi|October 1, 1988
[Measurement of Gla proteins by dot method and clinical study (protein S, protein C, and prothrombin)]A Osaki
International Journal of Oncology|May 5, 2011
Relative effects of immunohistochemical expressions of c-erbB-2, p53, and bcl-2 oncoproteins on the survival of advanced breast cancer patients after endocrine therapyA Osaki, Y Nomura
Current Hypertension Reviews|July 5, 2014
Nesfatin/Nucleobindin-2 (NUCB2) and Glucose HomeostasisH Shimizu, A Osaki
International Journal of Oncology|October 18, 2001
A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: the paradoxical role of Bcl-2 oncoprotein (review)R Kim, A Osaki, T Toge
Breast Cancer Research and Treatment|January 1, 1995
Long term survival and the prognostic factors of advanced breast cancer patients treated with adreno-oophorectomyY Nomura, H Tashiro, A Osaki
Journal of Biochemistry|March 1, 1994
Dissociation of dimer of bovine erythrocyte Cu,Zn-superoxide dismutase and activity of the monomer subunit: effects of urea, temperature, and enzyme concentrationK Inouye, A Osaki, B Tonomura
Oncology|September 1, 1995
A multivariate analysis of prognostic factors including tumor response after endocrine therapy in advanced breast cancer patientsY Nomura, H Tashiro, A Osaki
Nutrition & Diabetes|March 8, 2016
Transgenic mice overexpressing nesfatin/nucleobindin-2 are susceptible to high-fat diet-induced obesityH Shimizu, M Tanaka, A Osaki
Oncology Reports|August 10, 2001
Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancerR Kim, A Osaki, T Toge
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Epidermal growth factor receptor expression as a prognostic indicator in breast cancerM Toi, A Osaki, H Yamada, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Nihon Sanka Fujinka Gakkai Zasshi|October 1, 1988
[Measurement of Gla proteins by dot method and clinical study (protein S, protein C, and prothrombin)]A Osaki
International Journal of Oncology|May 5, 2011
Relative effects of immunohistochemical expressions of c-erbB-2, p53, and bcl-2 oncoproteins on the survival of advanced breast cancer patients after endocrine therapyA Osaki, Y Nomura
Current Hypertension Reviews|July 5, 2014
Nesfatin/Nucleobindin-2 (NUCB2) and Glucose HomeostasisH Shimizu, A Osaki
International Journal of Oncology|October 18, 2001
A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: the paradoxical role of Bcl-2 oncoprotein (review)R Kim, A Osaki, T Toge
Breast Cancer Research and Treatment|January 1, 1995
Long term survival and the prognostic factors of advanced breast cancer patients treated with adreno-oophorectomyY Nomura, H Tashiro, A Osaki
Journal of Biochemistry|March 1, 1994
Dissociation of dimer of bovine erythrocyte Cu,Zn-superoxide dismutase and activity of the monomer subunit: effects of urea, temperature, and enzyme concentrationK Inouye, A Osaki, B Tonomura
Oncology|September 1, 1995
A multivariate analysis of prognostic factors including tumor response after endocrine therapy in advanced breast cancer patientsY Nomura, H Tashiro, A Osaki
Nutrition & Diabetes|March 8, 2016
Transgenic mice overexpressing nesfatin/nucleobindin-2 are susceptible to high-fat diet-induced obesityH Shimizu, M Tanaka, A Osaki
Oncology Reports|August 10, 2001
Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancerR Kim, A Osaki, T Toge
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Epidermal growth factor receptor expression as a prognostic indicator in breast cancerM Toi, A Osaki, H Yamada, et al.
Pageof 3